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Abstract 
 
Cholesterol crystals are known to be a hallmark of atherosclerosis with recent studies 
demonstrating deposition of these crystals in early fatty streak formation as well as penetrating 
the intima following plaque rupture. Inflammation has also become a central focus in atheroma 
development and endothelial cell activation is recognized as necessary for the recruitment of 
inflammatory cells to the plaque. However, the extent to which cholesterol crystals can induce 
inflammation and activate endothelial cells is not known. To investigate this, we developed a 
novel model activating human umbilical vein endothelial cells using lepirudin anticoagulated 
human whole blood. We found that cholesterol crystals caused a marked and dose-dependent 
increase in the adhesion molecules E-selectin and ICAM-1 on the surface of the endothelial cells 
after incubation with whole blood. There was no activation of the cells when the crystals were 
incubated in medium alone, or in human serum, despite substantial crystal-induced complement 
activation in serum. Complement inhibitors at the C3 and C5 levels reduced the whole blood 
induced endothelial cell activation by up to 89% (p < 0.05) and abolished TNF release (p < 
0.01). Finally, the TNF inhibitor infliximab reduced endothelial activation to background levels 
(p < 0.05). In conclusion, these data demonstrate that endothelial activation by cholesterol 
crystals is mediated by complement-dependent TNF release, and suggests that complement-
inhibition might have a role in alleviating atherosclerosis-induced inflammation. 
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Introduction 
 
Cardio-vascular diseases are a major cause of mortality world wide, and although 
survival has improved over recent years, there are many facets of these diseases not yet well 
understood. Atherosclerosis is frequently implicated in diseases such as stroke, myocardial 
infarction and aortic aneurisms. Early on, cholesterol crystals (CC) were recognized as a 
hallmark of the late atherosclerotic plaque, and recent studies have also demonstrated its 
presence already at the development of the fatty streak being one of the earliest manifestations of 
atherosclerosis (Duewell et al., 2010). George Abela and his group have also demonstrate that in 
post-mortem examination of atherosclerotic plaque rupture, there are cholesterol crystals 
piercing the intima thus potentially playing a role in subsequent inflammatory reactions (Abela et 
al., 2009; 2010). 
Although first thought to be mainly a disease of lipid-deposition, today there are 
overwhelming data supporting a central role of inflammation both in atheroma development as 
well as its subsequent morbidity and mortality (Hansson and Hermansson, 2011; Hansson et al., 
2002; Libby et al., 2009). The complement system appears to play a role in this response, as 
several studies in mice and men have indicated complement deposition in atherosclerotic plaques 
as well as modulating effects of complement inhibition on atheroma formation (Francescut et al., 
2012; Haskard et al., 2008; Manthey et al., 2011; Niculescu and Rus, 1999; Speidl et al., 2011a; 
2011b; Torzewski and Bhakdi, 2013). The complement system is known to play a role in a large 
number of inflammatory diseases (Klos et al., 2009; Ricklin et al., 2010), where three separate 
activating pathways all converge on the splitting of C3 to C3b and C3a. C3a is a known 
inflammatory mediator, whereas C3b is both important for opsonisation as well as amplification 
	  	   4	  
and the formation of the C5-convertases (Ricklin et al., 2010; Sarma and Ward, 2011). The C5-
convertases splits C5 into C5a and C5b, where C5a is a potent inflammatory mediator which 
effects are mainly due to its interaction with the C5a-receptor (C5aR). C5b	  together	  with	  C6-­‐C9	  form	  the	  terminal	  C5b-­‐9	  complex	  (TCC),	  which,	  when	  activated	  on	  a	  surface	  form	  the	  membrane	  attack	  complex	  and	  might	  lyse	  bacteria	  or	  cells,	  or	  in	  sub-­‐lytic	  doses	  activate	  cells	  to	  produce	  inflammatory	  mediators.	  In	  the	  fluid	  phase,	  the	  TCC	  forms	  a	  soluble	  complex	  (sC5b-­‐9)	  which	  can	  be	  detected	  as	  a	  complement	  activation	  product	  in	  body	  fluids	  indicating	  ongoing	  complement	  activation	  (Ricklin et al., 2010; Sarma and Ward, 2011). 
Endothelial cells (EC) are known as well to play a role in inflammation, both being 
crucial for the recruitment of inflammatory cells and active producers of chemokines and 
cytokines. They are also for the same reasons central in atherosclerosis development. EC 
activation is a necessary prerequisite for leukocyte recruitment to the plaque (Guardamagna et 
al., 2009; Mai et al., 2013; Mestas and Ley, 2008; Pate et al., 2010). There are a long range of 
mediators that are shown to activate endothelial cells in vitro, among others TNF, IL-1β, sub-
lytic TCC and C5a (Pate et al., 2010), which all might be relevant in EC activation in 
atherosclerosis. 
Despite the presence of CC in the plaque, and the known role of inflammation in 
atherosclerosis there are limited data on the inflammatory potential of CC. Several groups have 
demonstrated the strong complement-activating potential of CC (Hasselbacher and Hahn, 1980; 
Seifert and Kazatchkine, 1987; Vogt et al., 1985). Two seminal studies also demonstrated that 
CC caused inflammasome activation in primed monocytes linking CC to Il-1β production, which 
is thought of as a central player in atherosclerosis development (Duewell et al., 2010; Rajamäki 
et al., 2010). In a recent study from our group, we have taken this one step further, showing that 
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CC-induced inflammation in whole blood is complement-dependent and that C5a combined with 
TNF are potent primers for CC induced inflammasome activation (Samstad et al., 2014).  
In this study we aimed to examine to what extent CC could activate EC. We developed a 
novel EC activation assay, co-incubating whole blood with monolayers of human umbilical vein 
endothelial cells (HUVEC) measuring the expression of adhesion molecules on the HUVEC 
surface post-exposure as a marker of activation. Using this model we found that when CC were 
incubated with whole blood there was a potent, complement-dependent EC activation, which was 
mainly mediated by TNF. 
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Materials and methods 
Reagents 
Sterile phosphate buffered saline (PBS) with and without Ca2+ and Mg2+ and 
Ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma–Aldrich (St. Louis, MO). 
CryoTubesTM (polypropylene) was purchased from Nunc AS (Roskilde, Denmark). Lepirudin 
(Refludan®) was purchased from Pharmion (Copenhagen, Denmark) and used at a final 
concentration of 50 µg/ml in whole blood. A 4% stock solution made of paraformaldehyde 
(PFA) was purchased from Sigma-Aldrich (St. Louis, MN). BSA 30% was purchased from 
Biotest (Dreieich, Germany) and Trypsin/EDTA was from Invitrogen (Carlsbad, CA). 
Recombinant human C5 were purchased from Quidel (San Diego, CA). Recombinant human 
TNF and recombinant human IL-1β were purchased from R&D systems (Minneapolis, MN). 
 
Antibodies used were FITC-conjugated mouse anti human ICAM-1 (CD54, Clone BBIG-I1), 
PerCP conjugated mouse anti-human MCAM (CD146, clone 128018) and iso-type controls 
(R&D Systems, Minneapolis, MN), PE conjugated mouse anti-human E-selectin (CD62E, clone 
1.2B6) and iso-type control (Southern Biotech, Birminham, AL), C5 antibody 
(eculizumab/Soliris®, Alexion), TNF antibody (infliximab/Remicade®, Janssen Biologics), anti- 
IL-1β (canakinumab/Ilaris®, Novartis) and anti-CD20 (rituximab/Mabthera®, Roche). C3-
inhibitor compstatin analog CP40 (Ac-Ile-[Cys-Val-Trp(Me)-Gln-Asp-Trp-Sar-Ala-His-Arg-
Cys]-mIle-NH2) and its control scrambled peptide (Qu et al., 2013) were a kind gift from 
Professor John D. Lambris, as was the the specific C5a-receptor antagonist (AcF[OPdChaWR]), 
synthesized as previously described (Finch et al., 1999). 
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Cholesterol crystals 
CC were produced as previously described (Samstad et al., 2014). Briefly, ultra-pure cholesterol 
(Sigma–Aldrich, St. Louis, MO) was dissolved in 1-propanol and aggregated by addition of 
sterile water. CC were then air-dried and tested for LPS which was below the detection limit in 
the limulus amebocyte lysate assay (0.3 pg/ml). CC were used at a final concentration of 2 
mg/ml (3 x 10^7 particles/ml) if not otherwise specified.  
Whole blood and HUVEC 
A modified version of an ex vivo whole blood model which was described in detail previously 
(Mollnes et al., 2002) was used. HUVEC (ECACC, Salisbury, UK) were seeded in 48-wells 
plates (Costar, Corning, New York) coated with 1% gelatin (Sigma, St. Louis, MO) and grown 
until confluence (2-4 days) in DMEM 199 medium (Invitrogen, Carlsbad, CA) with growth 
supplements and 7.5% fetal calf serum. All cells were used in passage 2-5. On the day of the 
experiment, fresh human whole blood was obtained from healthy donors and anticoagulated with 
lepirudin. Confluent HUVEC layers were washed once with sterile, 37°C PBS before the 
addition of 100 µl whole blood, growth medium, growth medium supplemented with 50% 
pooled human serum (NHS) or plasma from whole blood experiments to each well. The 
inhibitors compstatin (20 µM), eculizumab (100 µg/ml), C5aR-antagonist (10 µM), infliximab 
(100 µg/ml), canakinumab (100 µg/ml), rituximab as a control antibody (100 µg/ml) or PBS 
were added in a total volume of 20 µl and incubated for 4 minutes at 37∘C prior to stimulation 
with PBS, CC, recombinant TNF (0.1 - 10 ng/ml) or recombinant IL-1β (0.1 - 10 ng/ml). 
Samples were then incubated at 37°C with 5% CO2 for 4 hours with gentle shaking. Thereafter, 
whole blood or medium was removed and EDTA (20 mM) was added before centrifugation for 
15 min at 3000 x g at 4°C. Plasma or supernatant were stored at −70°C until analysis.  
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Endothelial cell activation markers 
After removal of medium, plasma or whole blood, HUVEC layers were gently washed twice 
with ice-cold PBS, and fixed with 0.5% PFA and incubated at 4°C for 2.5 minutes, according to 
a modified protocol from Gräbner et al. (Gräbner et al., 2000). After gentle washing with PBS, 
anti-ICAM-1-FITC, anti-E-selectin-PE or their iso-type controls, and anti-MCAM-PerCP were 
added and plates were incubated for 30 minutes at 4°C. Cells were washed twice with PBS, 
briefly trypsinated and transferred to 5 ml polypropylene tubes (Sarstedt, Nuernbrecht, 
Germany), washed with PBS with 0.1% BSA and run on a FACSCalibur or FACS LSRII flow 
cytometer (BD Bioscience, San Jose, CA). HUVEC were gated as MCAM positive cells. Median 
values were used for fluorescense intensity values (MFI). Data were analyzed either in 
FacsDIVA (BD Bioscience, San Jose, CA) or FlowJo X (Tree Star Inc, Ashland, OR).  
C5-deficient patient 
The C5-deficient (C5D) patient used for this study is previously described in details (Lappegård 
et al., 2009). In experiments with the C5D patients, C5D blood, C5D blood reconstituted with 
recombinant C5 (50 µg/ml), and two healthy controls were all run simultaneously on the same 
plate.  
Cytokine and complement measurements 
Analysis of plasma concentrations of IL-1β, IL-6, IL-8 and TNF were done using multiplex 
technology. Single-plex beads were purchased from Bio-Rad (Bio-Rad Laboratories Inc., 
Hercules, CA) and used according to manufacturer’s recommendations. The C5b-9 complex 
(TCC) was measured using a specific antibody aE11 which targets a C9 neo-epitope in an in-
house ELISA which was previously described in detail (Bergseth et al., 2013). 
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Statistics and ethical approval 
All data were compiled in Prism (GraphPad Inc. Version 5, San Diego, CA, USA). Groups were 
compared using one-way ANOVA for repeated measurements with Bonferroni’s post-test for 
comparisons of specific groups if not otherwise specified. Informed written consent was obtained 
from each donor, and the local ethics committee approved the study. 
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Results 
HUVEC incubated with whole blood 
As we already know that CC activate leukocytes and cause both the expression of leukocyte 
adhesion molecules and cytokine release in whole blood (Samstad et al., 2014), we here 
investigated to which extent CC incubated in whole blood would activate EC. In order to 
examine this, we developed a novel model, where we co-cultured lepirudin anti-coagulated 
whole blood with monolayers of HUVEC. Whole blood alone did not cause any visual 
alterations of the HUVEC layer as examined by light microscopy, and there were only minimal 
EC activation by whole blood compared to medium controls. Notably, the addition of CC to 
whole blood caused a dose-dependent increase in both E-selectin and ICAM-1 on the EC 
surface, with some donor-dependent differences. Two mg/ml was chosen as the optimal dose 
causing a robust activation compared to unstimulated samples (Figure 1).  
Effect of complement activation by CC on EC activation 
We next evaluated the role of complement inhibition on the EC surface expression of the 
adhesion molecules E-selectin and ICAM-1. These were significantly inhibited both at the C3 
level (compstatin) and at the C5 level (eculizumab and C5aR-antagonist), where E-selectin was 
attenuated by 70-89% (Figure 1A) and ICAM-1 by 61-82% (Figure 1B). We confirmed these 
finding using a C5-deficient patient, where incubation of CC in C5-deficient whole blood did not 
cause EC activation, however reconstitution with recombinant C5 increased activation to the 
level of healthy controls (Figure 2).  
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HUVEC incubated with CC in human serum 
To examine if the previously documented complement activation induced by CC could cause EC 
activation directly, we incubated CC with EC in medium containing 50% pooled human serum. 
Despite a robust production of TCC in the supernatant post-incubation, indicating substantial 
complement activation, no up-regulation of the adhesion molecules were observed (Figure 3).  
The role of TNF in EC activation 
Both TNF and IL-1β are regarded as early mediators in the cytokine response that are known to 
cause HUVEC activation in vitro, and	  we	  have	  previously	  demonstrated	  that	  TNF	  participate	  in	  the	  release	  of	  cytokines	  that	  are	  induced	  by	  CC	  in	  whole	  blood (Samstad et al., 2014). We 
therefore examined if either of these cytokines was important for CC-induced EC-activation. 
Using a specific inhibitor towards TNF (infliximab) or IL-1β (canakinumab) we evaluated the 
impact of these cytokines on HUVEC activation. Whereas IL-1β inhibition did not affect E-
selectin or ICAM-1 expression, inhibiting TNF completely attenuated these responses (Figure 4), 
demonstrating that TNF plays a central role in CC induced EC activation.  
 To explore the role of TNF further, we evaluated to what extent other cytokines in CC- 
activated whole blood would participate in EC activation. In order to do this, we pre-activated 
whole blood with CC to generate all relevant cytokines, then activated EC using plasma from 
these experiments (Figure 5 A and B). Where indicated infliximab, canakinumab or a control 
antibody was added prior to stimulation of EC. As whole blood incubated without activators also 
caused a moderate activation of EC, we included plasma isolated from whole blood at the point 
of blood sampling (T0) as an additional control. The TNF inhibitor infliximab reduced EC 
activation to under the level of plasma from unstimulated whole blood experiments and towards 
background (T0) activation, demonstrating the key role of TNF (Figure 5 A and B). We also 
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found a dose-dependent response of HUVEC to TNF and IL-1β (Figure 5 C and D), as well as 
full inhibition of this activation by infliximab and canakinumab demonstrating the efficacy of the 
inhibitors (Figure 5 C and D). 
 
Complement and TNF 
The cytokine responses to CC are to a large extent dependent on complement activation as we 
have earlier demonstrated that complement inhibition attenuated these responses in whole blood 
(Samstad et al., 2014). Since TNF-inhibition completely attenuated the CC-induced EC 
activation, we addressed whether complement inhibition reduces TNF release in plasma from 
CC-activated whole blood and EC. Inhibition at the C5-level completely abrogated CC induced 
IL-1β, IL-6, IL-8 and TNF release, supporting the central role of TNF in EC-activation in this 
model and that TNF release occurs down-stream to complement activation (Figure 6).  
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Discussion 
In this study we have established a novel model of HUVEC activation allowing us to study the 
complex interaction between EC and both cellular and humoral immune-components in fresh 
whole blood. Using this model, we found that CC were not able to activated EC directly, or in 
serum alone, but indirectly through whole blood, and that this activation was complement-
dependent. Surprisingly, we also found that TNF single handedly seems to mediate this 
activation.  
HUVEC have for a long time been used as a model system for EC activation. However, 
the activation of HUVEC with addition of activating substances to medium does not capture the 
complexity of EC activation, nor does it allow examination of the relative contribution of 
different mediators towards EC activation in more complex systems. To more accurately model 
this complexity, some have used conditioned media to activate EC (Nooteboom et al., 2006; 
2005; 2004; 2002; Schildberger et al., 2011), that is medium from activated leukocytes or 
immortalized monocyte cell lines as well as medium mixed with plasma from heparin anti-
coagulated whole blood. However there are limitations to these models as well, as molecules 
with short half-life, for instance C5a, the role of cell-cell interaction between EC and leukocytes, 
as well as the modulating role of EC on leukocyte and complement activation cannot be 
captured. Therefore we developed a novel model of HUVEC activation, where we co-incubated 
monolayers of HUVEC with lepirudin anticoagulated whole blood to examine the complex 
interaction of EC, leukocytes, platelets, the complement system, and other lesser known players 
in the inflammatory network. This allowed us not only to look at EC activation in a more 
physiologically complex system, but also attempt to dissect the relative importance of EC-
activating mediators in this system. 
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The role of CC in inducing inflammation is not well elucidated, but we have previously 
shown that CC occur early on in atherosclerotic lesions (Duewell et al., 2010) and that CC cause 
inflammasome activation in LPS primed macrophages (Duewell et al., 2010). Recently, we 
linked complement to CC-induced inflammasome activation in a human whole blood system 
(Samstad et al., 2014), and found that C5a and TNF in combination act as a potent priming signal 
in isolated monocytes for CC induced inflammasome activation (Samstad et al., 2014). As 
endothelial activation is central in leukocyte recruitment to atherosclerotic plaques, we examined 
to what extent CC can participate in EC activation. Our data demonstrate that CC are potent 
activators of the whole blood system, and that this activation causes up-regulation of EC 
adhesion receptors thus supporting the inflammatory potential of CC in atherosclerosis. 
We found earlier that in CC-induced inflammation in whole blood, both cytokine 
production as well as leukocyte activation, were dependent on complement activation (Samstad 
et al., 2014). In the present study inhibition of the complement system completely abolished CC-
induced activation of EC by whole blood, strengthening our hypothesis that complement is 
central in CC-induced inflammation. This was the case both with inhibitors at the C3 and C5 
level and as an antagonist directed at the C5 receptor had similar effects as the other inhibitors, 
our study indicates that C5a is the major player. Using a patient with a well-established C5-
deficiency we confirmed the findings as reconstitution with recombinant C5 caused a clear 
increase in CC induced EC activation. A recent study found that sublytic TCC and not C3a/C5a 
caused IL-1β production in murine dendritic cells (Laudisi et al., 2013), but our study does not 
indicate that the sublytic TCC is of importance in neither human whole blood activation 
(Samstad et al., 2014), nor whole blood induced EC activation. 
	  	   15	  
There are a some studies indicating that activation of the complement system itself can 
cause activation of HUVEC by increased adhesion molecule expression both through C5a and 
sublytic TCC (Foreman et al., 1994; Tedesco et al., 1997), as well as cytokine production, 
mainly IL-8 and MCP-1, and NFκB activation (Albrecht et al., 2004; Kilgore et al., 1996; 1997; 
Monsinjon et al., 2003; Selvan et al., 1998) . However, other studies have not been able to 
reproduce findings on C5a and sublytic TCC-induced increase of EC adhesion molecule 
expression (Jagels et al., 2000; Kilgore et al., 1995; Monsinjon et al., 2003). Our study support 
the latter findings, as directly stimulating HUVEC with CC in pooled human serum did not cause 
activation of the cells, despite potent complement activation in the serum. Although we cannot 
exclude the possibility that the observed increase in adhesion molecule expression is modulated 
by complement interaction with EC (Kilgore et al., 1995), our study indicates that complement 
activation products do not activate EC directly, but EC activation is caused by mediators 
dependent on complement activation in whole blood.  
In vitro studies have found a large number of activators of HUVEC, but TNF and IL-1β 
are singled out as central in causing EC activation (Haraldsen et al., 1996; Mantovani et al., 
1997; Nooteboom et al., 2002). Particularly, Nooteboom et al. found that upon activating EC 
with plasma from LPS activated whole blood, the increase of E-selectin and ICAM-1 seen were 
completely abolished when a combination of IL-1β and TNF inhibitors were used (Nooteboom et 
al., 2004). We have also established that CC cause both IL-1β and TNF production in whole 
blood	  (Samstad et al., 2014), and thus we here examined if inhibiting these cytokines also would 
reduce CC-induced EC activation. We used clinically available antibodies, namely infliximab 
(anti-TNF) and canakinumab (anti- IL-1β) to evaluate the role of these cytokines in our model. 
We found that both inhibitors completely inhibited activation by recombinant TNF and IL-1β 
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when used at 10 ng/ml demonstrating the efficacy of the inhibitors. However, when whole blood 
was incubated with CC and the inhibitors, infliximab completely abolished EC activation, 
whereas canakinumab had no effect on EC adhesion molecule expression, indicating that TNF 
plays the main role in EC activation caused by CC. Testing the dose-response curve of HUVEC 
for both TNF and IL-1β we found that both cytokines dose-dependently caused activation. 
Nevertheless within the time frame of our experiment, there was only a limited IL-1β production, 
which did not reach the activating levels found in the dose-response curves. Furthermore, we 
have shown earlier that CC also induce IL-1ra in whole blood, known to inhibit IL-1β activity 
(Samstad et al., 2014), thus a combination of these factors could explain the lack of effect of IL-
1β inhibition. Therefore we cannot exclude the possibility that IL-1β can play an important role 
in EC activation in the long run as we know that monocytes have a robust IL-1β response to CC 
after 10-16 hours (Samstad et al., 2014). 
We have shown earlier that TNF inhibition also reduces the overall cytokine response to 
CC in whole blood (Samstad et al., 2014). To examine to what extent the effect of the TNF 
inhibitor was due to direct interaction between TNF and HUVEC or whether TNF inhibition 
modulated either leukocyte activation or the general inflammatory reaction to CC, we incubated 
whole blood with CC without HUVEC for 4 hours, and used the plasma from these experiments 
to activate HUVEC. CC-induced activation could then run its course, without TNF inhibition of 
leukocyte activation or cytokine production. When we added the TNF inhibitor to the plasma 
prior to activation of HUVEC, the inhibitor still caused an almost complete attenuation of the 
induced EC activation, indicating that the main effect of TNF inhibition in our model is directly 
through reducing TNF-EC interaction.  
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To investigate if the effect of the complement inhibitors could be due to their role in 
reducing TNF release, we measured cytokine production in plasma from the whole blood and 
HUVEC experiments. We found that the complement inhibitors reduced the production of all 
four cytokines measured, reducing TNF almost to background levels. This indicates that reduced 
TNF production is one of the mechanisms behind the effect of complement inhibition, and again 
support the central role of TNF in CC-induced EC activation. 
Thus, somewhat surprisingly, despite the large number of potential EC-activating factors 
produced in whole blood inflammation, we found that TNF singlehandedly was responsible for 
the activation seen in our model. Although TNF has been suggested as an important mediator in 
simpler EC activation models, our study confirms these findings in a more complex system, and 
demonstrate that other activators shown to activate in vitro, such as sub-lytic TCC and C5a play 
a minor role, if any role at all in our model. This warrants further research into the relative 
importance of TNF and other mediators with other sources of inflammation, as one cannot 
assume that factors shown to cause EC activation in vitro necessarily play a significant role as 
the complexity of the system increases. 
 With our novel HUVEC activation model using whole blood, we have shown that CC 
contribute to the inflammatory state of EC, which could be relevant in atherosclerotic diseases. 
Although, CC did not cause direct activation of EC, they did cause a potent activation of EC 
when co-incubated with whole blood, an activation which was complement-dependent. 
Interestingly, we also demonstrate that in our model, this complement-dependent activation is 
nearly completely mediated by TNF.  
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Figure Legends 
Figure 1: CC-induced EC-activation is complement dependent 
EC were incubated with whole blood and complement inhibitors or control antibody prior to the 
addition of 2 mg/ml CC. (A) E-selectin expression and (B) ICAM-1 expression given as mean ± 
SEM for 5 healthy donors. ns = non significant, * p < 0.05, ** p< 0.01, *** p < 0.001 as 
compared to CC stimulation. 
 
Figure 2: CC induced EC activation is attenuated in C5-deficient patient 
EC were incubated with whole blood from a confirmed C5-deficient patient with or without 
reconstitution with 50 µg/ml recombinant C5 or with whole blood from healthy controls. (A) E-
selectin expression and (B) ICAM-1 expression on EC were measured. Four separate 
experiments were performed for the C5-deficient patient, with in total eight separate healthy 
controls. Data are given as mean ± SEM. 
 
Figure 3: CC incubated in 50% serum induce robust complement activation but no EC 
activation 
Expression of E-selectin and ICAM-1 on EC after incubation with 50% NHS in EC medium 
(both on right axis) as well as TCC production in supernatant (left axis) after stimulation with an 
increasing dose of CC. Data given as mean of n=3 ± SEM. 
 
Figure 4: EC activation is mediated by TNF 
EC were incubated with whole blood and the TNF antibody infliximab, the IL-1β antibody 
canakinumab or control antibody prior to the addition of 2 mg/ml CC. (A) E-selectin expression 
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and (B) ICAM-1 expression given as mean ± SEM of n=6 donors for all groups except 
canakinumab with n=4. ns = non significant, * p < 0.05, *** p < 0.001 as compared to CC 
stimulation. 
 
Figure 5: TNF-EC interaction is the main cause of EC activation 
Whole blood was incubated with or without 2 mg/ml CC for 4 hours after which plasma was 
separated and frozen immediately at − 80°C. Plasma was also separated from same donor but 
without incubation (T0). After thawing plasma on ice, EC were incubated with plasma from T0 
(white), without CC (light gray) or with CC (dark gray), and where stated, infliximab, 
canakinumab or a control antibody was added to the plasma. (A) E-selectin and (B) ICAM-1 
were measured. HUVEC was also incubated in medium with increasing doses of TNF (C) or IL-
1β (D) which dose-dependently increased expression of E-selectin and ICAM-1 which were 
inhibited by their respective inhibitors infliximab (anti-TNF) and canakinumab (anti-IL-1β). All 
data given for mean ± SEM of n=3 donors, except the lowest dose in panel C and D where n=2. 
ns = non significant, **** p < 0.0001 as compared to CC stimulated plasma 
 
Figure 6: Complement inhibition attenuates cytokine release in whole blood 
Plasma from whole blood incubated with EC, CC and inhibitors was analyzed for (A) IL-1β, (B) 
IL-6, (C) IL-8 and (D) TNF. Data are given as mean ± SEM for n=6 donors. ns = non significant, 
** p < 0.01, *** p < 0.001 as compared to CC stimulation. 
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